Understanding the regulation of the mTOR pathway is of paramount importance in renal cancer as inhibitors of mTOR (everolimus and temsirolimus) which are structural analogs of rapamycin are clinically approved for the treatment of advanced metastatic cancer. Here, MTOR is linked to metastatic malignant neoplasm.